

Hamilton Regional Laboratory Medicine Program - HRLMP (effective at Hamilton Health Sciences, St. Joseph's Healthcare and Associated Health Care Facilities)		
Initial Issue Date: Revision Date:	Administration Guidelines	Section: Laboratory Medicine Sub-Section: Transfusion Medicine
Title: ANTIHEMOPHILIC FACTOR (RECOMBINANT)		Document Number:
<i>Approved By:</i> <i>Director, Laboratory Medicine</i> <i>Chair, Regional Transfusion Medicine Committee</i> <i>Head, Transfusion Medicine, HRLMP</i> <i>Manager, Transfusion Medicine, HRLMP</i> <i>Technical Specialist, Transfusion Medicine, HRLMP</i> <i>Chief of Nursing Practice, Hamilton Health Sciences</i> <i>Chief of Nursing Practice, St Joseph's Healthcare</i>		Page 1 of 3

Purpose: To Establish the Indications and Administration of Antihemophilic Factor (Recombinant)

Scope: All patient care areas across HHS and St. Joseph's Healthcare

Definitions: Recombinate - is formulated as a sterile, non-pyrogenic lyophilized powder preparation of concentrated recombinant antihemophilic factor for intravenous injection

Other Names: RECOMBINATE (rAHF) Recombinant Factor VIII	Date Approved:	Pages: 1 of 3
--	-----------------------	----------------------

<p>INDICATIONS:</p> <ul style="list-style-type: none"> - Hemophilia A for prevention and control of hemorrhagic episodes - Peri-operative management of patients with hemophilia A - May be used in patients with acquired AHF inhibitors not exceeding 10 Bethesda units/ml
<p>DOSAGE:</p> <ul style="list-style-type: none"> - Each vial labeled with AHF activity expressed in international units (IU) - In vivo peak increase expressed as IU/dl or percent; can be estimated by multiplying dose administered/Kg by 2 - Following dosage schedule can be used as a guide: - (e.g.: peak level of 70% is required in 40 Kg child with baseline level of <1% - dose would be 70/2 X 40 = 1400 IU).

ANTIHEMOPHILIC FACTOR (RECOMBINANT)

Page 2 of 3

SUPPLIED:

- Single dose bottled 250, 500 and 1000 IU per bottle with 10 ml injectable sterile water to reconstitute
- Store refrigerated between 2°C to 8°C
- Do not use beyond expiry date

RECONSTITUTION AND STABILITY:

- Preparation (including reconstituting, filtering, and pooling if required) is performed in transfusion Medicine
- See Manufacturer's information (package insert) for further information
- Reconstituted product should be used immediately

ADMINISTRATION:

- Prior to administration, patient and product identification must be verified
- Withdraw using syringe with administration needle or a vented infusion set

METHOD	WHO/WHERE	DILUTION	HOW TO ADMINISTER	INFUSION PUMP	PRECAUTIONS AND MONITORING
IV PUSH	RN/Physician	No	-Administer filtered product with administration needle -Rate up to 10 mL/min	No	-Observe and monitor for adverse reactions
MINIBAG/ BURETROL	RN	No	-Administer filtered product using a buretrol or sterile bottle with a vented administration set -Rate up to 10mL/min	Can be used	-Observe and monitor for adverse reactions
PRIMARY IV BAG	N/A	N/A	N/A	N/A	N/A
IM or SC	NA	NA	NA	NA	NA

COMPATIBILITIES/INCOMPATIBILITIES:

- Should not be used if known hypersensitivity to mouse, hamster or bovine protein
- Studies have not been done with AHF in pregnant women (it is not known whether it can cause fetal harm or can affect reproductive capacity — should only be given to pregnant women if clearly needed)

ADVERSE EFFECTS:

- Reactions are extremely rare, although nausea, fever, chills or urticaria, anaphylaxis, hypotension and chest constriction have been reported

MANAGEMENT OF ADVERSE EFFECTS:

- Notify physician
- Notify Transfusion Medicine
- Antihistamine and steroids could be used as concurrent treatment as a precautionary measure
- Epinephrine should be available for treatment of severe allergic systems

NOTES:

- Manufactured by Baxter Corporation
- Distributed by Canadian Blood Services

Documentation:

Issue transfuse sheets or requisitions with lot numbers must be included in patient's chart
Written consent for transfusion must be obtained prior to transfusion

References:

Package insert-Baxter Antihemophilic Factor (Recombinant), Baxter Healthcare Corporation, February 2000.

Developed By In Consultation With

Transfusion Medicine Operations Group
Hemophilia Nurse Coordinator

REVIEW DATES:

REVISION DATES: